Multicenter Trial of Stem Cell Therapy for Osteoarthritis (MILES) (MILES)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03818737|
Recruitment Status : Completed
First Posted : January 28, 2019
Last Update Posted : March 15, 2023
- Study Details
- Tabular View
- Results Submitted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Osteoarthritis||Biological: Bone Marrow Derived MSCs Biological: Adipose-derived MSCs Biological: Umbilical Cord Tissue (UCT) MSCs Drug: Corticosteroid injection||Phase 3|
Primary osteoarthritis is a debilitating disease characterized by extensive damage to the joints and excruciating pain leading to loss of activity and depression. Despite advances in diagnosis and relatively efficient control of nociception, to date, the quest for the development of a disease modifying osteoarthritis drug has proven unsuccessful. The potential of mesenchymal stem cells (MSCs) to inhibit inflammation while promoting healing makes them amenable for the treatment of various ailments ranging from cancer to genetic diseases. In orthopedic practice, autologous stem cell injections are performed to alleviate the pain associated with osteoarthritis. A serious gap in knowledge remains whether the currently used cellular treatments are beneficial in the long term and if one cell therapy outperforms another.
The most popular form of autologous MSC therapy has been through the use of autologous bone marrow concentrate (BMAC). The rationale is that when a sample of bone marrow aspirate (BMA) is collected and the components that are not beneficial to the joint are filtered out (i.e. red blood cells, neutrophils, etc.) the remaining concentrate (MSCs, platelets, interleukins, etc) can have a "healing" effect on the environment in which it is injected. However it is still unknown as to how effective BMAC is for treating orthopedic conditions compared to other MSC procedures and the most important components of the BMAC mixture that could aid patients suffering from osteoarthritis.
Adipose tissue has been found to have a large amount of MSCs versus that in bone marrow. These cells are currently being used in a variety of clinical research studies within the regenerative medicine field. Through a tissue process which includes washing and centrifuging, the cellular components can be extracted as a cell pellet, which is also known as stromal vascular fraction (SVF). Adipose derived SVF is obtained via liposuction, or the removal of adipose tissue via a suction method.
Although the use of various stem cell preparations for knee osteoarthritis has become increasingly prevalent, well-designed studies with conclusive proof of comparative effectiveness and identification of the optimal cell source and "dose" have not been performed. This study is the first randomized study comparing three types of cellular treatments to corticosteroids. The main objective of the study is to identify a superior source of stem cells for the treatment of osteoarthritis and validate its advantages over corticosteroid injections as the traditional gold standard treatment.
Participants will be randomized study arms with different types of MSCs (bone marrow derived MSC, adipose derived MSC, and umbilical cord tissue MSC) and then will be further randomized to receive an injection of the MSC type they were initially assigned to or corticosteroid. Participants randomized to bone marrow derived MSC or adipose derived MSC will undergo a procedure (bone marrow aspiration or liposuction). Participants will be blinded to whether they receive the MSC or corticosteroid injection.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||480 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||The study will include a parallel design using a blocked central randomization scheme of 1:1:1:1. Participants will first be randomized to have MSCs derived from either bone marrow, adipose tissue, or umbilical cord tissue. Then they will be further randomized to receive either an injection of MSCs (from bone marrow, adipose, or umbilical cord tissue, depending on the first randomization) or a corticosteroid injection.|
|Masking Description:||Participants will not know if they are receiving the MSC or corticosteroid injection.|
|Official Title:||Randomized Multicenter Phase 3 Single-blind Trial Comparing the Efficacy of Corticosteroid Control to Mesenchymal Stem Cell Preparations From Autologous Bone Marrow Concentrate (BMAC), Adipose-derived Stem Cells in the Form of Stromal Vascular Fraction (SVF), and Third-party Human Mesenchymal Stem Cells Manufactured From Umbilical Cord Tissue for the Treatment of Unilateral Knee Osteoarthritis (OA)|
|Actual Study Start Date :||March 28, 2019|
|Actual Primary Completion Date :||May 31, 2022|
|Actual Study Completion Date :||May 31, 2022|
Experimental: Bone Marrow Derived MSCs
Participants randomized to this arm will undergo bone marrow aspiration and then will be further randomized to receive a standard orthobiologic injection into the knee joint of autologous bone marrow concentrate (BMAC).
Biological: Bone Marrow Derived MSCs
Autologous bone marrow concentrate (BMAC) is a standard orthobiologic injection for knee osteoarthritis.The procedure involves harvesting of bone marrow aspirate (BMA) from the posterior superior iliac spine (PSIS) and then following centrifugation in an FDA approved device (EmCyte GenesisCS Pure BMAC®-60 ml) will be injected back into the knee joint. All injections will be made via ultrasound guidance using a standard approach.
Experimental: Adipose-derived MSCs
Participants randomized to this arm will undergo small volume lipoplasty, and then will be further randomized to receive an injection into the knee joint of adipose-derived stromal vascular fraction (SVF).
Biological: Adipose-derived MSCs
Adipose-derived Stromal Vascular Fraction (SVF) will be obtained from a mini lipoaspirate. The lipoaspirate will then be enzymatically digested to produce a SVF that will be injected into the knee joint. All injections will be made via ultrasound guidance using a standard approach.
Experimental: Umbilical Cord Tissue (UCT) MSCs
Participants randomized to this arm will receive an injection into the knee joint of cryopreserved doses of umbilical cord tissue MSCs.
Biological: Umbilical Cord Tissue (UCT) MSCs
Cryopreserved doses of umbilical cord tissue MSCs will be used. These MSCs were cryopreserved at P2 culture in plasmalyte A + 5% human serum albumin in 5 finger cryobags containing 20 million cells in 4 mL and stored under liquid nitrogen until shipment. Cells will be transported in a dry shipper and thawed at the study sites. The dose of MSCs will be aspirated from the cryobag into a sterile syringe and directly injected into the knee. All injections will be made via ultrasound guidance using a standard approach.
Active Comparator: Corticosteroid Injection
Participants randomized to the bone marrow derived MSC, adipose-derived MSC, or umbilical cord tissue MSC study arms will be further randomized within the arm in a 3:1 ratio to receive either MSCs derived from the study arm of the initial randomization or a corticosteroid (CS) injection. Participants randomized to the control group will receive an injection of corticosteroid into the knee joint.
Drug: Corticosteroid injection
The corticosteroid injection is prepared by mixing 1cc of 40mg/dL depomedrol and 6cc of normal saline in a 10cc syringe will be made into the knee joint. All injections will be made via ultrasound guidance using a standard approach.
- Change in Visual Analog Pain Scale (VAS-pain) Score [ Time Frame: Baseline, 1 month, 3 months, 6 months, 9 months, 12 months ]Pain assessment will be done using the Visual Analog Pain Scale (VAS-pain). The VAS-pain is self-completed by the participant. The respondent is asked to place a line perpendicular to the VAS line at the point that represents their pain intensity. Using a ruler, the score is determined by measuring the distance (mm) on the 10-cm line between the "no pain" anchor and the participant's mark, providing a range of scores from 0-100. The recommended cut points for VAS are: no pain (0-4 mm), mild pain (5-44 mm), moderate pain (45-74 mm), and severe pain (75-100 mm).
- Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) - Pain Subscale Score [ Time Frame: Baseline, 1 month, 3 months, 6 months, 9 months, 12 months ]The KOOS questionnaire assesses the participant's opinion about their osteoarthritis and associated problems. It consists of 5 subscales; pain, symptoms, activities of daily living (ADL) function, sport and recreation function, and knee related quality of life (QoL). The pain subscale has 9 items and response options are given on a 5-point Likert scale where 0 = no problems and 4 = extreme problems. Scores are transformed to a scale ranging from 0 to 100 with 0 indicating extreme symptoms and 100 indicating no symptoms.
- Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) - Total Score [ Time Frame: Baseline, 1 month, 3 months, 6 months, 9 months, 12 months ]The KOOS questionnaire assesses the participant's opinion about their osteoarthritis and associated problems. It consists of 5 subscales; pain, symptoms, activities of daily living (ADL) function, sport and recreation function, and knee related quality of life (QoL). The KOOS has 42 items across all subscales and response options are given on a 5-point Likert scale where 0 = no problems and 4 = extreme problems. The sum of subscale scores is transformed to a scale ranging from 0 to 100 with 0 indicating extreme symptoms and 100 indicating no symptoms.
- Change in EuroQuality of Life (EQ-5D-3L) Index Score [ Time Frame: Baseline, 1 month, 3 months, 6 months, 9 months, 12 months ]The EQ-5D-3L survey measures the severity of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participants will be asked to answer questions regarding these measures and to indicate their current experience on a scale from 1 to 3 (1 being "no problem" and 3 being "most extreme problem"). A sixth item asks participants to rate their current heath from 0 (worst imaginable) to 100 (best imaginable). The answers to these question are converted into an index value based on the country respondents live in. Health state index scores typically range from less than 0 to 1, where 0 is a health state equivalent to death and 1 is perfect health.
- Change in Patient-Reported Outcomes Measurement Information System (PROMIS 29) Score [ Time Frame: Baseline, 1 month, 3 months, 6 months, 9 months, 12 months ]The PROMIS-29 assesses seven health domains: physical function, anxiety, depression, fatigue, sleep disturbance, pain interference, and ability to participate in social roles and activities. Each of the seven domains has four questions which are scored on a five-point Likert scale. The PROMIS-29 scales are scored using a T-score metric method available at the Assessment Center website (http://assessmentcenter.net). A score of 50 points represents the population average for each scale, and 10 points represent one standard deviation. Scores higher than 50 indicate more of the specific scale's construct, which may indicate a desirable or an undesirable outcome.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||40 Years to 70 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Age greater or equal to 40 but less than or equal to 70 years old
- Males and females
- Recent knee radiograph of the targeted knee (standing anteroposterior (AP) lateral and sunrise view)
- Diagnosis of OA in the targeted knee (radiographic evidence of OA in the medial and/or lateral tibiofemoral compartment, which would include one or more osteophytes on a standard radiograph taken within 3 months)
- Continued OA pain in the targeted knee despite conservative measures (per treating provider's discretion)
- Average daily VAS ≥3
- Kellgren-Lawrence system of Grade II, III, or IV
- Subjects may have concomitant patellofemoral but they must have stage II or higher generalized knee OA
- Females of childbearing potential only, must have a negative pregnancy test done at screening prior to enrollment in the study
- Women and men of child-producing potential must agree to use acceptable contraception methods for the duration of the trial such as birth control pills or condoms with spermicide
- Clinically apparent tense effusion of the targeted knee
- Significant valgus/varus deformities (+/- 10 degrees)
- Viscosupplementation within 6 months in the targeted knee
- Other biologic injection (PRP or stem cell) within 1 year in the targeted knee
- Surgery in the targeted knee within the past 6 months (either open or scope)
- Systemic or intra-articular injection of corticosteroids in any joint within 3 months before screening
- Daily opioid use for the past three months
- History of malignancy in the previous 5 years prior to study entry, with the exception of in-situ cancers treated only by local excision with curative intent
- History of, or ongoing, autoimmune disorder that requires treatment with an immunosuppressive medication
- Active, suspected, or prior infection to the joint in the targeted knee
- Part of a vulnerable population per Office for Human Research Protections (OHRP) definition (pregnant women and breast-feeding women, cognitively impaired, prisoners, etc.)
- Unwilling to discontinue the use of Non-Steroidal Anti-Inflammatory (NSAID)s for 7 calendar days prior to the procedure
- Unwilling to discontinue use of NSAIDS for 5 calendar days after procedure
- History of bleeding disorders or inflammatory joint disease
- Inability to hold anti-platelet therapy according to treating provider prior to procedure
- Subject is, in the opinion of the investigator, unable to comply with the requirements of the study protocol or is unsuitable for the study for any reason
- Uncontrolled diabetes
- Subject has an active workers' compensation case in progress with targeted knee
- Subject with insufficient amount of subcutaneous tissue
- Hemoglobin less than 10g/dL at the time of screening
- Leukocytes <3,000/μL; neutrophils <1,500/μL; lymphocytes <800/μL; platelets <100,000/μL at the time of screening
- Diagnosis of liver disease as defined by alanine aminotransferase (ALT) >3x the upper limit of age-determined normal (ULN) or total bilirubin > 1.5x ULN
- Subjects who have had greater than 3 corticosteroid injections in the targeted knee in the 12 months prior to screening or at the physician's discretion
- Subjects with a known diagnosis of osteoporosis
- Subjects with anticipated use of systemic corticosteroids during the study period for treatment of a chronic medical condition
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03818737
|United States, Florida|
|Gulf Breeze, Florida, United States, 32561|
|United States, Georgia|
|The Emory Clinic|
|Atlanta, Georgia, United States, 30322|
|United States, North Carolina|
|Durham, North Carolina, United States, 27710|
|United States, North Dakota|
|Fargo, North Dakota, United States, 58103|
|United States, South Dakota|
|Sioux Falls, South Dakota, United States, 57104|
|Study Director:||Hicham Drissi, PhD||Emory University|
|Principal Investigator:||Scott D Boden, MD||Emory University|
|Responsible Party:||Scott D Boden, Professor, Emory University|
|Other Study ID Numbers:||
|First Posted:||January 28, 2019 Key Record Dates|
|Last Update Posted:||March 15, 2023|
|Last Verified:||March 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
|Product Manufactured in and Exported from the U.S.:||Yes|
mesenchymal stem cells
bone marrow aspiration
adipose-derived stromal vascular fraction
Peripheral Nervous System Agents
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists